Why the study?
Does thoracic endovascular aneurysm repair (TEVAR) improve outcomes compared to medical management with anti-impulse therapy in patients with type B aortic dissection?
Does thoracic endovascular aneurysm repair (TEVAR) improve outcomes compared to medical management with anti-impulse therapy in patients with type B aortic dissection?
Answers are grounded in this paper and cite their sources.
The authors argue for the broader application of TEVAR in type B aortic dissection, contrasting it with traditional medical management.
With rapid advances in thoracic endovascular aneurysm repair (TEVAR) technology, and with increasing adoption of this procedure by the cardiovascular community, its role in the management of type B aortic dissection (TBAD) continues to evolve. Traditionally, medical management with anti-impulse therapy has been advocated for TBAD. In a retrospective study of 100 consecutive patients with TBAD, the early survival rate was as high as 91%.1 This study also reported that 66% of these survivors had an uncomplicated long-term course with anti-impulse therapy.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: